A 35‐year‐old male presented with an extremely itchy exanthem after Pfizer–BioNTech COVID‐19 vaccination.1 A single oval erythematous lesion appeared on the thigh after the first dose (a) and progressed insidiously to a papulosquamous rash on the trunk and proximal extremities (b). After the second dose, it notably flared up (c). Serological evaluation for human herpesvirus reactivation was negative. Pityriasis rosea‐like eruption was diagnosed.2 Antihistamines and topical betamethasone were initiated, with clinical improvement after 2 weeks. Considering that immunization programmes are being conducted worldwide, it is important to increase awareness within the medical community, so that appropriate management be provided.
Author Contribution
Ana María Carballido Vázquez: Conceptualization (equal); Data curation (equal); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (equal). Bruno Morgado: Conceptualization (equal); Data curation (equal); Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (equal).
Contributor Information
A.M. Carballido Vázquez, Department of Dermatology University Hospital of Valladolid Valladolid Spain
B. Morgado, Faculty of Medicine and Biomedical Sciences University of Algarve Faro Portugal Hospital Center of Vila Nova de Gaia/Espinho Vila Nova de Gaia Portugal.
References
- Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med 2020; 383:2603–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea‐like eruptions: how to distinguish them? JAAD Case Rep 2018; 4:800–1. [DOI] [PMC free article] [PubMed] [Google Scholar]